Year To Quarter End Consolidated Statement Of Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7608023

Concept 2021-04-01 to
2021-12-31
2021-04-01 to
2021-12-31
2021-04-01 to
2021-12-31
2021-04-01 to
2021-12-31
2021-04-01 to
2021-12-31
Year to quarter end consolidated statement of income
Statement of income
Net sales
44,179,000,000 JPY
44,221,000,000 JPY
-41,000,000 JPY
39,685,000,000 JPY
4,536,000,000 JPY
Cost of sales
23,485,000,000 JPY
Gross profit (loss)
20,694,000,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
16,017,000,000 JPY
Operating profit (loss)
4,677,000,000 JPY
5,173,000,000 JPY
-495,000,000 JPY
4,886,000,000 JPY
286,000,000 JPY
Non-operating income
Interest income
0 JPY
Dividend income
251,000,000 JPY
Non-operating income
367,000,000 JPY
Non-operating expenses
Interest expenses
43,000,000 JPY
Non-operating expenses
254,000,000 JPY
Ordinary profit (loss)
4,790,000,000 JPY
Extraordinary income
Gain on sale of non-current assets
9,425,000,000 JPY
Extraordinary income
9,425,000,000 JPY
Extraordinary losses
Impairment losses
5,921,000,000 JPY
Extraordinary losses
8,366,000,000 JPY
Profit (loss) before income taxes
5,849,000,000 JPY
Income taxes - current
1,048,000,000 JPY
Income taxes - deferred
717,000,000 JPY
Income taxes
1,766,000,000 JPY
Profit (loss)
4,082,000,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
4,082,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
61,000,000 JPY
Remeasurements of defined benefit plans, net of tax
22,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
89,000,000 JPY
Other comprehensive income
173,000,000 JPY
Comprehensive income
4,256,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
4,256,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.